News of Note—Fresenius recalls 163 lots of sodium chloride

Cancer in newspaper clipping
(Pixabay)

> Fresenius Kabi USA is voluntarily recalling 163 lots of Sodium Chloride Injection, because the labels incorrectly state that the stoppers do not contain latex. Release

> Ian Hudson, M.D., chief executive of the Medicines and Healthcare Products Regulatory Agency, has announced he will retire from MHRA in September 2019. Pharmafield article

> CDMO Dalton Pharma Services has a drug development and manufacturing services agreement with stem cell biotech ExCellThera for formulation and fill/finish services at its plant in Toronto, Canada. Release

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> Oxford BioMedica will invest £4 million to build digital and robotics capabilities to increase capacity, reduce the cost of manufacturing and reduce waste in its cell manufacturing. Release

Suggested Articles

The FDA is allowing some drugmakers to exceed the level of risk from a probable cancer-causing impurity in losartan for six months.

CDMOs Cambrex and Ajinomoto Bio-Pharma Services upgraded manufacturing plants, Takeda scored an albumin approval via its Shire deal, and more.

The FDA hit United Exchange Corp. with a warning letter, citing the company for a number of “significant” violations with its quality-control systems.